Protocol Single compound
Cagrilintide
Long-acting amylin analog
Acylated amylin analog used in laboratory research on amylin/calcitonin receptor signaling.
Compare side by side →Laboratory reference · in vitro research data
- Research vial sizes
- 5 mg
- Dosing data
- Not listed — reference entry covers vial concentration only.
- Storage
- Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Reconstitution concentrations
Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.
| Vial | BAC water | mg/mL | mg per 10 u |
|---|---|---|---|
| 5 mg | 1 mL | 5 | 0.5 |
| 5 mg | 2 mL | 2.5 | 0.25 |
| 5 mg | 3 mL | 1.67 | 0.167 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Syringe
Research dossier · published literature summary
01
Mechanism of action
Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety. It is studied alone and combined with semaglutide (CagriSema).
02
Observed research endpoints
- Phase 2 (26 weeks): every cagrilintide arm reduced weight more than placebo (6.0%–10.8% vs 3.0%); the top arm also beat liraglutide (10.8% vs 9.0%).
- REDEFINE 1 (3,417 adults without diabetes): cagrilintide–semaglutide gave −20.4% mean weight change at 68 weeks vs −3.0% with placebo.
- REDEFINE 2 (type 2 diabetes): −13.7% vs −3.4% with placebo at 68 weeks.
03
Regulatory & safety context
- Investigational: not approved as a standalone medicine.
- Phase 2: gastrointestinal events in 41%–63% vs 32% on placebo, mainly nausea. REDEFINE 1: gastrointestinal events in 79.6% vs 39.9%.
04
Citations
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. Lancet. 2021;398(10317):2160–2172.2021-12Phase 2 randomized controlled trialRead paper ↗
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635–647.2025-08Phase 3a randomized controlled trialRead paper ↗
- Davies MJ, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025;393(7):648–659.2025-08Phase 3a randomized controlled trialRead paper ↗
Keep exploring
Related compounds
Found in these stacks & blends
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
View productView COA
Supplier C
TBDPlaceholder — details coming soon
View productView COA